- Home
- NEE vs AMGN Comparison
NEE vs AMGN Comparison
Compare NEE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEE
- AMGN
- Stock Information
- Founded
- NEE 1925
- AMGN 1980
- Country
- NEE United States
- AMGN United States
- Employees
- NEE N/A
- AMGN N/A
- Industry
- NEE Electric Utilities: Central
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEE Utilities
- AMGN Health Care
- Exchange
- NEE Nasdaq
- AMGN Nasdaq
- Market Cap
- NEE 154.7B
- AMGN 141.6B
- IPO Year
- NEE N/A
- AMGN N/A
- Fundamental
- Price
- NEE $70.76
- AMGN $272.11
- Analyst Decision
- NEE Buy
- AMGN Buy
- Analyst Count
- NEE 15
- AMGN 22
- Target Price
- NEE $86.60
- AMGN $324.05
- AVG Volume (30 Days)
- NEE 10.2M
- AMGN 3.5M
- Earning Date
- NEE 01-24-2025
- AMGN 02-04-2025
- Dividend Yield
- NEE 2.91%
- AMGN 3.50%
- EPS Growth
- NEE N/A
- AMGN N/A
- EPS
- NEE 3.38
- AMGN 7.83
- Revenue
- NEE $26,246,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- NEE N/A
- AMGN $20.07
- Revenue Next Year
- NEE $9.81
- AMGN $3.59
- P/E Ratio
- NEE $20.96
- AMGN $34.74
- Revenue Growth
- NEE N/A
- AMGN 21.25
- 52 Week Low
- NEE $53.95
- AMGN $253.30
- 52 Week High
- NEE $86.10
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- NEE 46.36
- AMGN 54.19
- Support Level
- NEE $68.89
- AMGN $267.15
- Resistance Level
- NEE $72.68
- AMGN $272.82
- Average True Range (ATR)
- NEE 1.40
- AMGN 4.68
- MACD
- NEE 0.18
- AMGN 2.37
- Stochastic Oscillator
- NEE 71.72
- AMGN 75.60
About NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 34 GW of generation capacity, including natural gas, nuclear, wind, and solar.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.